Topfond Pharmaceutical Co., Ltd. (hereinafter referred to as "Topfond Pharmaceutical") is a large-scale comprehensive pharmaceutical enterprise integrating science, industry and trade, mainly engaged in the production and sales of dosage forms, chemical synthesis API and biological fermentation API as well as pharmaceutical business.

        Founded in 1969, Topfond pharmaceutical was listed in Shanghai stock exchange in December 2000. After more than 40 years of hard work, Topfond has grown from small to large, from weak to strong, and now it has developed into a large pharmaceutical group with 5 subsidiaries, 4 production branches and 1 state-recognized technology development center, with more than 4000 employees and a total asset of more than 4 billion yuan.Topfond’s finished preparation production scale and antibiotic raw material fermentation capacity rank the forefront of the same industry in China.In August 2008, Topfond joined China General Technology Group. In July 2013, Topfond successfully realized the share exchange, absorption and merger with China Meheco Group Co., Ltd., and was formally incorporated into the management of China Meheco.

        Topfond pharmaceutical products mainly involve antibiotics, cardiovascular and cerebrovascular diseases, anti-AIDS, diabetes and other fields.The production and storage of more than 10 dosage forms of nearly 600 varieties and specifications of products.It has an annual production capacity of 10 billion tablets (pellets) of oral solid preparations with antibiotic fermentation capacity of 12000m3. APIs and some pharmaceutical products are exported to more than 30 countries and regions in Western Europe, Southeast Asia, the Middle East, North Africa, etc., which have successfully integrated into the tide of global economic integration.Computer ERP system has been used in production, scientific research, management, circulation and other systems.